drugset
drugset / Trial / NCT00354016

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

NCT00354016 ↗

Phase 3 Completed 125 enrolled Novartis Novartis Vaccines · collab
Non-randomizedSingle-groupOpen-labelPrevention

Summary

Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO (World Health Organization) and CHMP (Committee for Medicinal Products for Human Use) recommendations. Immunogenicity and tolerability of the newly composed vaccines are subject for evaluation in a yearly clinical trial in non-elderly and elderly subjects (CPMP/BWP/214/96).

Timeline

Start
2006-07
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Inactivated Split Influenza Vaccine Vaccine — —

Indications

influenza